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A new, predominantly single chain preparation of re-
combinant tissue-type plasminogen activator was eval-
uated to determine coronary thrombolytic efficacyin 100
patients with acute myocardial infarction. At 3.6 ± 1.2
hours (mean ± SD) from symptom onset, patients re-
ceived either intravenous tissue plasminogen activator
(1.25 mg/kg body weight over 3 hours) or placebo on a
3:1 randomized, double-blind basis. Coronary angiog-
raphy, performed 68 ± 13 minutes after initiation of
the study drug infusion, demonstrated patency of the
infarct-related artery in 40 (57%) of 70 patients in the
tissueplasminogenactivator group compared with3 (13%)
of 23 patients in the placebo group (p < 0.001). Patients
in the placebo group were then eligible to receive intra-
coronary streptokinase. At 90 minutes the patency was
observed in 49 (69%) of71 tissue plasminogen activator
patients compared with 5 (24%) of 21 placebo patients
With the introduction of cell culture-derived tissue-type
plasminogen activator, clot-selective thrombolysis became
possible on a pilot scale (1-5). Recombinant DNA tech-
niques allowed amplification of production, enabling large-
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(p < 0.001). At 120 minutes patency was observed in 59
(79%) of 75 patients of the tissue plasminogen activator
group and in 10 (40%) of 25 in the intracoronary strep-
tokinase/placebo group.
A nadir value of <100 mg/dl fibrinogen occurred in
8 (11%) of 73 patients receiving tissue plasminogen ac-
tivator versus 8 (40%) of 20 patients treated with intra-
coronary streptokinase (p =0.002). Moderate or severe
bleeding episodes occurred in 39% of patients treated
with tissue plasminogen activator compared with 32%
of patients who received placebo/intracpronary strep-
tokinase (p = NS). Thus, this tissue plasminogen acti-
vator preparation achieves a high rate of recanalization
and, at the doses employed, exhibits increased fibrinogen
sparing compared with intracoronary streptokinase.
oAm Coli CardioI1987;9:120S-13)
scale clinical investigation. The first preparation of recom-
binant tissue plasminogen activator produced on a small
scale for initial clinical testing was predominantly a two-
chain form (G11021) because of cleavage at the molecule's
arginine-275-isoleucine 276 peptide bond. Although several
clinical studies in acute myocardial infarction have dem-
onstrated the efficacy of tissue plasminogen activator G11021
(6-10), clot selectivity at moderate doses (~80 mg) was
relative rather than absolute (11,12).
A new recombinant tissue plasminogen activator (G11035),
manufactured on a large scale for clinical use, was found
to be predominantly single chain (Genentech data on file).
The focus of this study was to evaluate the coronary throm-
bolytic efficacy of this new tissue plasminogen activator
preparation in a randomized, double-blind, placebo-con-
0735-1097/87/$3.50
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trolled trial in acute myocardial infarction. Secondary end
points of this investigation included the effect of tissue plas-
minogen activator on the coagulation and fibrinolytic pro-
teins, bleeding complications and the role of coronary an-
gioplasty.
Methods
Patient selection. This study was conducted at four cen-
ters with respective institutional review board approval. Pa-
tients were enrolled during a 5 month period, between Sep-
tember 1985 and February 1986. Inclusion criteria were: 1)
chest discomfort longer in duration than 20 minutes and
shorter than 6 hours and unresponsiveness to sublingual
nitroglycerin; and 2) electrocardiographic (ECG) ST seg-
ment elevation of > 1 mm in two contiguous leads. Patients
were excluded if they presented with cardiogenic shock or
had had previous coronary artery bypass surgery, a prior
transmural infarct in the same myocardial territory, recent
«3 months) head trauma or stroke, major surgery in the
past 2 weeks or a history of a bleeding diathesis.
During the study, a total of 109 patients met entry criteria.
Of these, nine were excluded, four because a catheterization
laboratory was unavailable, three because they refused to
participate, one because there was no suitable vascular ac-
cess site and one because of an episode of hemoptysis just
before entry.
Protocol. Patients at each institution were randomized
on a 3:1 basis to either tissue plasminogen activator or
placebo, respectively. The study medication was adminis-
tered on a double-blind basis as soon as informed consent
was obtained. The dose of intravenous tissue plasminogen
activator was 0.75 mg/kg body weight over the first hour
with 10% given as a bolus, and 0.25 mg/kg per h over the
subsequent 2 hours. A total maximal dose of 105 mg of
tissue plasminogen activator was given even though 32 pa-
tients who were randomized to this agent weighed >80 kg.
Using a single wall needle puncture and the Judkins tech-
nique, coronary arteriography of the infarct-related vessel
was performed serially at 60, 90 and 120 minutes after
initiation of the study drug infusion. At the first angiogram,
performed at least 60 minutes into therapy, the infarct-re-
lated vessel patency status, classified according to the throm-
bolysis in myocardial infarction (TIMI) grading system (8),
was determined and the randomization code was broken to
determine whether the study drug was tissue plasminogen
activator or placebo.
As defined by the TIMl study group (8). TIMI grade 0
= "no perfusion" with no anterograde flow beyond the
point of occlusion; TIMI 1 = "penetration without per-
fusion" such that contrast agent fails to opacify the coronary
bed distal to the obstruction; TIMI 2 = "partial perfusion":
contrast filling is delayed or its clearance is delayed, but
contrast material opacifies the distal coronary bed; and TIMI
3 = "complete perfusion": a normal pattern of contrast
filling and clearance (8).
Those patients with persistent occlusion who had re-
ceived placebo were eligible to receive intracoronary strep-
tokinase (a 20,000 U bolus and 2,000 to 4,000 Ulmin over
60 rninutes). Patients initially randomized to tissue plas-
minogen activator or placebo who manifested hemodynamic
deterioration (systolic blood pressure <90 mm Hg, require-
ment for vasopressors) during the course of therapy were
considered for emergent coronary angioplasty.
After the 120minutepoint. patientswere treatedas clin-
ically indicated; coronary angioplasty was performed im-
mediately (at 120 minutes of thrombolytic therapy) in 64
patients on the basis of experience and availability at each
particular clinical site. Successful angioplasty was defined
as <50% residual coronary stenosis and a normal flow (TIMI
3) pattern after completion of the procedure. One patient
underwent emergency coronary artery bypass surgery for
significant left main coronary artery stenosis. All patients
were maintained on intravenous heparin, with 5,000 U given
after arterial access and a continuous infusion of 800 to
1,000 U/h to keep the activated partial thromboplastin time
at 1Yz to 2 times that of the control value. Patients received
intravenous lidocaine (1 mg/kg bolus and a 2 to 4 mg/min
infusion) for the first 24 hours.
Hematologic and bleeding evaluation. Blood samples
were collected for the assay of coagulation and fibrinolytic
components before and 45 minutes, 2 and 6 hours and 1
and 7 days after the beginning of the infusion. Blood was
centrifuged within 1 hour and plasma frozen immediately.
All assays were performed centrally in the thrombolysis core
laboratory at the University of Vermont, Burlington. Plasma
fibrinogen levels were measured in plasma samples obtained
from blood collected on 0.01 M citrate (final concentration)
and 200 kll.l/rnl aprotinin (Trasylol). Fibrinogen levels were
measured by both a coagulation rate assay (13) and a sodium
sulfite precipitation (14); fibrinogen-fibrin degradation prod-
ucts (fdp) were assayed by the tanned red cell agglutination
inhibition method (15). Plasminogen was determined on
citrated plasma with the chromogenic substrate S-2251 after
conversion to plasminogen-streptokinase complex, accord-
ing to the instructions of the manufacturer (Kabi Vitrum).
Tissue plasminogen activator antigen levels were measured
on plasma samples collected on 0.01 M citrate as previously
described (16) and factor V and factor VIII levels were
determined, also as previously described (17).
Bleeding wascharacterized by siteand qualified as minor
if it had no clinical consequence, moderate if greater than
that usually observed in the clinical setting but with <250
ml estimated blood loss and severe if the blood loss was
>250 ml, required transfusion or was retroperitoneal or
intracranial. In patients receiving transfusion, the indication
was determined. In some patients who received transfusion,
there was no explanation (observed blood loss) for a sig-
JACe Vol. 9. No.6
June 1987:1205- 13
TOPOL ET AL.
I-PA IN MYOCARDIAL INFARCTION
1207
Table l. Clinical and Baseline Angiographic Data in 100 Patients
t-PA
(n = 75)
Placebo
(n = 25) p Value
Age(yr)
Sex
Time from chest pain to study med (h)
Infarct vessel
LAD
RCA
LCx
Unidentifiable
Mullivessel disease
526 ± 10.1
57M. 16F
3.6 ± 1.4
33(44%)
35(47%)
6(8%)
1(1%)
39(52%)
56.2 ± 11.5
19M,6F
3.6 ± l.l
12(48%)
10(40%)
3(12%)
0(0%)
14(56%)
NS
NS
NS
NS
NS
NS
NS
F = female; LAD = left anterior descending coronary artery; LCx = left circumflex artery; M = male;
med = medication; RCA = right coronary artery; t-PA = tissue plasminogen activator.
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Figure I. Comparison of infarct-related vessel (IRA) patency for
the two treatments as a function of time. At the three times of
angiographic evaluation, there was a significant increase in patency
of tissue plasminogen activator (open columns) compared with
placebo/intracoronary streptokinase (IC SK)-treated (hatched col-
umns) patients . *p < 0.001.
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angiograms was noted in 7 of 59 patient s in the plasminogen
activator group , of whom 5 exhibited reocclusion either later
during the catheterization procedure or after leaving the
laboratory .
Coronary angioplasty and follow-up arteriography.
A flowchart for infarct-related vessel status and triage to
immediate coronary angioplasty is shown in Figure 2. Among
the 75 patients receiving tissue plasminogen activator, 12
of the 16 patients who failed to demon strate infarct vessel
patency underwent coronary angioplasty after 120 minutes
of infusion . In two of these , the procedure was unsuccessful
and three patients demonstrated reocclu sion on follow-up
arteriography . Among the 59 patients who demon strated
patency after tissue plasminogen activator therapy, 34 had
acute angioplasty of the infarct-related artery. In 30 (88%)
of the 34, the procedure was successful (residual stenosis
<50% and TIMI grade 3 recanalization). Among the re-
maining four patients, two developed intimal dissection and
Results
nificant drop in hematocrit. In these patients. the indication
for transfusion was defined as augmentation of a low he-
matocrit.
Statistical analysis. All values are expressed as mean
± 1 SD. A 2 x 2 chi-square contingency table was used
to compare thrombolytic efficacy in tissue plasminogen ac-
tivator versus placebo patients . Statistical significance of
differences between groups in fibrinogen, fibrin degradation
products, plasminogen and factors V and VIII were estab-
lished by an unpaired t test.
Infarct-related vessel patency. Relevant clinical and
baseline angiographic data are summarized in Table I . In-
farct-related vessel patency of TIMI grade 2 or 3 (8) was
achieved in 40 (57%) of 70 patients in the tissue plasmin-
ogen activator group versus 3 (13%) of 23 patients in the
placebo group at the first (68 ± 13 minutes) angiogram (p
< 0 .(01) . Then 17 of 21 placebo patient s were crossed over
to intracoronary streptokinase. At the 90 minute angiogram,
the percent of patient s demon strating TIMI grade 2 or 3
perfusion in the tissue plasminogen activator and the pla-
cebo/streptokinase group was 69% (49 of 71 patients) versus
24% (5 of 21 patients ), respectively (p < 0.001 ; Fig. I).
By this time four patient s in the placebo/streptok inase group
had undergone coronary angioplasty because of hemody-
namic deterioration. At 120 ± 4 minutes, 59 (79%) of 75
tissue plasm inogen activator treated patient s and 10 (40%)
of 25 placebo/streptokinase patients had demon strated pat-
ency (p < 0,001 ).
The denominator of infarct vessel patency as expre ssed
for each interval represents the total number of patients who
had angiography performed at that time . A small number
of patients in both groups did not have angiography at the
60 or 90 minute point becau se of difficultie s in obtain ing
access or the delay of interhospital transport. Intermittent
patency and occlusion during serial (60,90 and 120 minutes)
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Figure 2. Flow chart of the treatment ran-
domization and percutaneous transluminal
coronary angioplasty (PICA) triage. The first
row shows the 3:I treatment randomization,
thesecond row theinfarct vessel status at 120
minutes after initiation of therapy of recom-
binant tissue plasminogen activator (rt-PA) and
60 minutes of placebo (before intracoronary
streptokinase) . Thethird row shows the num-
ber of patients who underwent coronary an-
gioplasty in each group.
recurrent ischemia and underwent coronary artery bypass
grafting, and two had unsuccessful angioplasty without
complications. The results for combined t-PA and coronary
angioplasty are shown in Figure 3.
In the placebo/streptokinase group, 17 of 21 patients
received intracoronary streptokinase for persistent TIMI grade
oor 1 flow (Fig. 2). Of these, 6 (35%) exhibited recanal-
ization within 1 hour after the initiationof streptokinase and
16 of the 21 underwent acute coronary angioplasty. Angio-
plasty was successful in achieving or augmenting recanal-
ization in 14 (88%) of the 16 patients.
In seven patients who did not undergo angioplasty im-
mediately, including one whose artery reoccluded and re-
canalized after repeat dosing of t-PA, this procedure was
performedlater becauseof postinfarction ischemia. The fol-
lOW-Up arteriographic data are incomplete with an overall
66% of patients (63 of 95 surviving patients) undergoing
repeat study. The incidence rate of late (7 ± 3 days) an-
giographically documented infarct vessel patency was 73%
(19 of 26) in patients with combined therapy (tissue plas-
minogen activator-mediated patency and immediate angio-
plasty) versus 64% (16 of 25) in those patients who dern-
onstrated patency with tissue plasminogen activator but did
not undergo coronary angioplasty (p = NS).
Clinical outcomes. Death occurred in five patients in
the trial, all within 48 hours of hospital admission. In the
two placebo group patients who died, cardiogenic shock
was present by the 90 minute point of infusion and reca-
nalization with coronary angioplasty was subsequently un-
successful . One patient had a proximal right coronary artery
occlusion and the other a left anterior descending coronary
artery occlusion with underlying severe three vessel coro-
nary artery disease. Failure of tissue plasminogen activator
to achieve proximal left anterior descending artery reper-
fusion occurred in two of the three patients who died in the
tissueplasminogen activatorpatientgroup. The other patient
had tissue plasminogen activator-mediated reperfusion and
coronary angioplasty but sustained a massive anterior in-
farction and developed cardiogenic shock 8 hours after ad-
mission.Therehavebeen no furtherdeathsat a meanfollow-
up time of 5.5 ± 2 months.
Postinfarction ischemia, documented by recurrent chest
pain and ECG changes, occurred in patients in the 12 tissue
plasminogen activator group and 2 in the placebo group (p
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~ 0
PTCA Success PTCA Falure
IL\
000
Patent OCCluded No
at FlU at FlU FlU
SUccessful rt-PA-> PleA
!\
~ 0
PTCA Success PTCA Faiure
,~\~\
Patent OCcluded No Emergency Med
at FlU at FlU FlU CABG Ax
Figure3. Flow chart of combined tissue plasminogen
activator (rt-PA) and coronary angioplasty (PTCA)
therapy. At left , the results for the 12 patients with
unsuccessful rt-PA treatment who underwent angio-
plasty are shown. At right, the clinical and angio-
graphic results of the 34 patients who had infarct vessel
patency after rt-PA and underwent immediate (same
sitting) angioplasty are shown. CABG = coronary ar-
tery bypass surgery; FlU = follow-up angiography at
7 to to days; Med Rx = medical therapy.
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Death
Post-MI angina
Reinfarction
Reocclu sion
Congestive heart failure
Pericarditis
Coronary artery bypass grafting
Arrhythmias
Ventricular tachycardia
Ventricular fibrillation
Atrioventricular block
t-PA
(n = 75)
3(4%)
12(16%)
3(4%)
12(16%)
13( 17%)
5(7%)
5(7%)
15(20%)
3(4%)
3(4%)
Placebo
(n = 25)
2(8% )
2(8%)
1(4%)
3(12%)
5(20%)
2(8%)
1(4%)
3(12%)
3(12%)
3(12%)
p Value
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
Ml = myocardial infarction; I·PA = tissue plasminogen activator .
= NS). In four other patients, reinfarction was confirmed
by recurrent enzymatic creatine kinase , MB fraction ele-
vation . The incidence of reinfarction was not different in
the two treatment groups (Table 2). Angiographic confir-
mation of reocclusion was made in 12 (24%) of 51 tissue
plasminogen activator-treated patients versus 3 (25%) of
12 placebo group patients who underwent repeat angiog-
raphy (p = NS). Thus, subclinical or " silent" reocclusion
occurred in at least eight patients (8%) in the trial . Table 2
presents data on congestive heart failure , defined as a new
requirement for digoxin and furosemide therapy; pericar-
ditis, defined as the presence of a friction rub and pleuritic
chest pain; referral for coronary artery bypass surgery ; and
arrhythmias noted during or after therap y.
Bleeding and hemostatic function. Most of the bleed-
ing complic ations in this trial were periaccess and overall
these were more prevalent among patients treated with tissue
plasminogen activator. Significant bleeding complications
occurring in the first 72 hours after initiation of therapy are
shown in Table 3. A severe periaccess hemorrhage in one
placebo group patient resulted in hypotension and transfu-
sion of 6 units of packed red cells. One patient who under-
went emergency coronary artery bypass grafting after re-
ceiving tissue plasminogen activator, developed a posterior
fossa intracranial hemorrhage 48 hours later. The hematom a
was evacuated and the patient had no residual neurologic
deficit. The 48 hour hiatus from tissue plasminogen activator
therapy and the interposition of open heart surgery make it
unlikely that the intracranial hemorrhage was secondary to
fibrinolytic therapy . In the other two patients who underwent
emergency bypass surgery , there were no significant bleed-
ing complications and no transfusion was required.
Transfusion of one or more units of blood was given to
22 (29%) of 75 patients receiving tissue plasminogen ac-
tivator and 4 ( 16%) of 25 receiving placebo (p = NS). In
the tissue plasminogen activator group , blood was given to
4 patients as part of coronary artery bypass surgery, to 14
to augment hematocrit (in absence of evident blood loss),
and to 4 to replace acute blood loss. In the pla-
cebo/streptokinase patient group , one patient received blood
to replace periaccess bleeding and the other three for he-
matocrit augmentation . The baseline and nadir hematocrit
values for the two groups of patients were not significantly
differen t: tissue plasminogen activator baseline 43 ± 5.3%,
nadir 35.5 ± 4.7%; placebo baseline 43 ± 4%, nadir 36
± 4. 3% (p = NS). Similarl y, the platelet count decreased
approximately 25% in both patient groups: tissue plasmin-
ogen activator baseline303 .4 ± 89,000 , nadir 230 ± 71,000;
placebo baseline 304 ± 53,000 . nadir 228 ± 45 ,000 (p =
NS).
Table 3. Bleeding Complications in 100 Patients
t-PA Placebo/SK*
(n = 75) (n = 25) P Value
Total patients* 29(39%) 9(32%) NS
Site of bleeding
Periaccess 20(26%) 2(8%) 0.05
Gastrointestinal 8(1 1%) 4( 16%) NS
Genitourinary 4(5%) 3(12%) NS
"Moderate or severe bleeding episodes and more than one bleeding complication occurred in three tissue
plasminogen activator (t-PA) and one placebo patient. SK = streptokinase.
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Discussion
Thrombolytic efficacy. We have demonstrated the ef-
ficacy of this predominantly single chain form of tissue
plasminogen activator (GII 035) in achieving infarct vessel
recanalization compared with placebo. Previous placebo-
controlled trials of thrombolytic therapy (6,10) have dem-
onstrated a similarrate of ' 'spontaneous" thrombolysis, that
is, approximately 20% of untreated patients demonstrating
a patent infarct vessel on early angiography. The patency
rates of 69% at 90 minutes and 79% at 120 minutes also
compare favorably with the data from previously published
trials (6-10, 18) which used the two-chain form of intra-
venous tissue plasminogen activator (G11021) (Table 5).
Although over time after the initial angiogram, thrombolytic
efficacy appeared to increase (57% at 60 minutes, 74% at
120 minutes) in tissue plasminogen activator-treated pa-
tients, this phenomenon could not be controlled for in pla-
cebo-treated patients. Serial intracoronary contrast injec-
tions, by transmission of the force of injectionand potential
vasodilatory effects of contrast medium itself, may promote
increased patency over time.
fibrinogen value at 45 minutes or 2 hours (r = - 0.0 1 and
- 0.16, respectively).
Samples from 62 patients drawn at baseline and between
7 and 47 (mean 22) days after treatment(223 samples) were
evaluated for the development of antibody to tissue plas-
minogen activator. A positive tissue plasminogen activator
antibody test, performed on day 7, occurred in only one
patient. Repeat tests in this patient at 12 and 19 days after
treatment were negative.
120
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The results of fibrinogen assays for the three patient
groups are shown in Figure 4. The results for the two assay
methods were comparable; the sodium sulfite precipitation
data are plotted (Fig. 3). Relevant coagulation and fibri-
nolytic protein data are presented in Table 4.
Tissue plasminogen activator antigen and antibody.
In the patients receiving tissue plasminogen activator, the
baseline tissue plasminogen activator antigen level was 16
± 8 ng/ml, which rose to 3,400 ± 1,600 ng/ml at 45
minutes and by 2 hours of infusion the level had fallen to
1150 ± 550 ng/ml. There was no correlation observed
between tissue plasminogen activator antigen level andplasma
Figure4. Effects ofthree different therapies onplasma fibrinogen.
The mean percent baseline fibrinogen plotted (standard deviation
is reported in text) versus time is reported from onset of infusion
for the patients treated with tissue plasminogen activator (rt-PA)
(n = 71), intracoronary streptokinase (SK) (n = 20) or placebo
(n = 4). There was no significant difference in the nadir of fi-
brinogen for the rt-PA and streptokinase treatment groups.
Table4. Hematologic Results in 97 Patients
t-PA
(n = 73)*
Streptokinase
(n = 20)*
Placebo Only
(n = 4)*
107 ± 20 98 ± 23 101 ± 19.6
55 ± 25 41 ± 20 68 ± 29.1
78.3 ± 22.5 77.1 ± 20.1 65 ± 31
51.9 ± 23. 1 40.8 ± 17.5 52 ± 28
139.5 ± 66 112.1 ± 45 99 ± 30
85.3 ± 44.9 76 ± 47.5 80 ± 36
Fibrinogen
nadir < 100 mg/dl
FDP titer (ng/ml)
(median)
Plasminogen
(% activity)
Baseline
6 hours
Factor V
(% activity)
Baseline
6 hours
Factor VIII
(% activity)
Baseline
6 hours
8(l1 %)t
1:4
8(20%)t
1:4
o
< 1:2
*Results are presented for those patients with samples obtained for the variable specified. Three patients
did not have complete samples. tp = 0.002. FDP = fibrinogen degradation products ; t-PA = intravenous
tissue-type plasminogen activator.
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Table 5. Clinical Trials of Intravenous Tissue-Type Plasminogen Activator in Acute
Myocardial Infarction*
Nadir
First Author No. ofPts. Recanalization Significant Fibrinogen
and Ref. Witht-PA Dose (%) Bleedingt (% Baseline)
Collen (6) 42 0.5 to 0.75 mg/kg 72 9 92
x 0.5 to 2 h
Williams (7) 47 80 mg/3 h 68 32 71
TIM! (8) 143 80 mg/3 h 66 6 to 10 67
Verstraete (9) 64 0.75 rug/kg 70 8 76
x 1.5 h
Verstraete (10) 64 0.75 rug/kg 61 2 52
x 1.5 h
Gold (19) 29 0.4 to 0.75 rng/kg 83 NR 62
x I to 2 h
Pooled - 389 68 2 to 32 68
*All studies were performed with the two chain (G11021) form . tAs defined in the respective trial. NR =
not reported; PIs. = patients.
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Role of coronary angioplasty. The preciserole of coro-
nary angioplasty after intravenous thrombolytic therapy re-
mains unclear. Althoughcoronary angioplasty was not per-
formed on a randomized basis in this multicenter trial, two
interesting observations can be made about the impact of
this technique on infarct vessel patency. First, in cases of
persistentocclusion the technique was successful in 88% of
patients. However, in those patients whose occluded vessel
failed to recanalize after tissue plasminogen activator ther-
apy, the long-term patency was reduced to only 50% of
those undergoing repeat study. Patientswho do not respond
to t-PA therapy are a very important subset because it is
precisely this group that stands to benefit the most from
urgent coronary arteriography and consideration for angie-
plasty. If failure to respond to tissue plasminogen activator
predicts an unfavorable response for coronary angioplasty,
the need for emergencycardiac catheterization may be less-
ened.
The second intriguingobservation about coronary angio-
plasty is the relatively high rate of late reocclusion (7 [18%]
of 40) , despite initialsuccess, Previous studies (19- 21) have
suggested a 10 to 16% incidence of reocclusion after an-
gioplasty in acute myocardial infarction. The explanation
for lack of sustainedpatencyafter mechanical recanalization
and use of concurrent antiplatelet and anticoagulation ther-
apy remainsto be elucidated. It is likely that residual throm-
bus at the site of the initial plaque rupture or high grade
stenosis plays a role. Other potential etiologic factors in-
clude vasospasm, balloon-induced intimal disruption or re-
perfusion injury with attendant decrease in flow.
Clinical outcome. The clinical outcomes for the two
groups of patients in this trial were relatively similar. In
light of the recent Italian randomized streptokinase (GISSI)
trial in acute myocardial infarction (22), it is clear that a
large sample size and early treatment are required to dern-
onstrate reduction in mortality and improvement in clinical
outcome with the use of early intravenous thrombolytic ther-
apy (23) . Although therapy with intravenous tissue plas-
minogen activator was initiated at 3.6 ± 1.2 hours from
the onset of symptoms, reperfusion was not obtainedbefore
4 .5 hours in most of the patients who demonstrated arteri-
ographic patency.
Bleeding and hemostatic function. The bleedingresults
in this trial are similar to those observed in previous studies
(6- 10, 18) of tissue plasminogen activator in acute myo-
cardial infarction. It is difficult to attribute the frequency of
periaccess bleeding to tissue plasminogen activator alone.
Indeed, such patients are treated concomitantly with intra-
venous heparin, undergo invasive punctures for access dur-
ing the cardiac catheterization and typically receive anti-
platelettherapy. Substantiatingthe importanceof theseother
factors , a recent study (24) in patients with myocardial in-
farction treated with direct coronary angioplasty showed no
difference in bleeding in this group compared with that in
patients receiving high dose intravenous streptokinase and
angioplasty. Thus. tissue plasminogen activator is only one
of several factors that promote bleeding in this clinical set-
ting. Although fibrinogen decreased to a nadir of 66% after
tissue plasminogen activator administration in our study,
the value decreased below 100mg/dl in only eight patients.
Intracoronary streptokinase (25) resulted in significant fi-
brinogen depletion, despite the low dose utilized and a low
rate (33%) of thrombolytic efficacy. In 40% of patients,
intracoronary streptokinase led to a nadir fibrinogen value
of < 100 rng/dl and recent studies (26) suggest that this
profound depletion is a prerequisite for coronary throm-
bolysis.
The discrepancy between the fibrinogen-sparing nature
of tissue plasminogenactivator and the need for transfusions
in this group of patients in the trial is apparent. Despite the
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relative lack of fibrinogen depletion and breakdown, tissue
plasminogen activator is an extremely potent fibrinolytic
(rather than fibrinogenolytic) agent. Thus, periaccess and
gastric mucosal sites may be at particular risk for increased
bleeding during tissue plasminogen activator infusion. The
heightened fibrinolytic efficacy of tissue plasminogen ac-
tivator compared with that of streptokinase has been pre-
viously documented (8,9) and it follows that unsuspected
sites of preformed fibrin may be more susceptible to lysis
with tissue plasminogen activator. However, this would be
anticipated chiefly during the infusion, particularly during
the high dose administered in the first hour. The marked
variability in peak plasma t-PA antigen level has been noted
previously (12,18) and was confirmed in our study; its cause
remains unclear.
Single and double chain preparations. The clinically
effective dose used in our study was 0.875 mg/kg of single
chain tissue plasminogen activator (G11035) over 90 min-
utes. Previous studies of tissue plasminogen activator in
acute myocardial infarction were performed with the two
chain form of tissue plasminogen activator (G 11021). The
effective dose over 90 minutes was 0.5 to 0.625 mg/kg.
Concurrent with our study, the National Heart, Lung, and
Blood Institute T1MI investigators (27) ascertained that this
dose was less effective when one chain tissue plasminogen
activator (G11035) was used. Pharmacokinetic studies in
primates and humans comparing GIl021 with Gil035 dem-
onstrate that G11035 is cleared approximately 40% more
quickly than is G11021, and therefore a higher initial dose
is necessary (Genentech, personal communication). How-
ever, this difference in pharmacokinetics is probably not
due to differences in percent of one and two chain tissue
plasminogen activator. When one chain is compared with
to two chain tissue plasminogen activator derived from a
portion of the same one chain tissue plasminogen activator,
the pharmacokinetic variables are indistinguishable. At the
doses employed in our trial, a high rate of recanalization
was observed with a comparable degree of fibrinogen spar-
ing as compared with the tissue plasminogen activator used
at lower doses in earlier trials (6-10).
Improved pharmacologic methods. Gold et a1. (18)
recently showed that a prolonged, low dose infusion of tissue
plasminogen activator is effective in sustaining infarct vessel
patency without compromising hemostatic variables. Reoc-
elusion was not systematically documented by a repeat cath-
eterization in our study, but 13 (18%) of 69 patients had
clinical and/or angiographic data, or both, to support reoc-
elusion. None of the patients in our study received a pro-
longed, low dose maintenance tissue plasminogen activator
infusion, which might have reduced this complication. An-
other important adjustment in dosing may be to administer
even higher doses of tissue plasminogen activator during
the first hour of therapy. Preliminary experience (28) with
90 mg over the first hour suggests that this is effective in
reducing the time to recanalization. At the intravenous dos-
ing utilized in this trial, the predominantly single chain
preparation of tissue plasminogen activator proved to be a
very effective agent in promoting coronary thrombolysis
with relative sparing of fibrinogen. The future clinical trials
in myocardial infarction and other thrombotic disorders may
help to establish the optimal dosing of this preparation.
We thank the referring physicians who made this study possible and Betty
Plunkett for preparation of the manuscript.
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University of Michigan, Ann Arbor, MI. Eva Kline, RN,
EricR. Bates, MD, JosephA. Walton,MD, PatrickD.V. Bourdillon,
MD, Gregory W. Baumann, MD, Bertram Pitt, MD.
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